On the polymorphism of griseofulvin: Identification of two additional polymorphs

Journal of Pharmaceutical Sciences

Volumn 102, Issue 2, 2013, Pages 462-468

  Mahieu, Aurelien ^a   Willart, Jean francois ^a   Dudognon, Emeline ^a   Eddleston, Mark D ^b   Jones, William ^b   Danède, Florence ^a   Descamps, Marc ^a  

^a UNIV LILLE   (France)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Calorimetry (DSC); Crystallization; Polymorphism; Solid state stability; Transformation

Indexed keywords

GRISEOFULVIN;

ARTICLE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; PROTON NUCLEAR MAGNETIC RESONANCE; X RAY DIFFRACTION;

EID: 84872497096     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23349     Document Type: Article

References (28)

1. Byrn SR, Pfeiffer RR, Stowell JG. 1999. Solid-state chemistry of drugs. Chevy Chase, Maryland: SSCI, Inc.
2. Hilfiker R. 2006. Polymorphism: In the pharmaceutical industry. Hoboken, New Jersey: John Wiley & Sons.
3. Brittain HG. 1999. Polymorphism in pharmaceutical solids. New York City, New York: Marcel Dekker.
4. Bernstein J. 2008. Polymorphism in molecular crystals. New York City, New York: Oxford University Press.
5. Yu L. 2010. Polymorphism in molecular solids: An extraordinary system of red, orange, and yellow crystals. Acc Chem Res 43(9):1257-1266.
6. Singhal D. 2004. Drug polymorphism and dosage form design: A practical perspective. Adv Drug Deliv Rev 56(3):335-347.
7. Byrn SR, Xu W, Newman AW. 2001. Chemical reactivity in solid-state pharmaceuticals: Formulation implications. Adv Drug Deliv Rev 48(1):115-136.
8. Brittain HG, Grant DJW. 1999. Effects of polymorphism and solid-state solvation on solubility and dissolution rate. In Polymorphism in pharmaceutical sciences, drugs and the pharmaceutical sciences; Brittain HG, Ed. New York City, New York: Marcel Dekker, pp 279-330.
9. Morris K. 2001. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv Drug Deliv Rev 48(1):91-114.
10. Datta S, Grant DJW. 2004. Crystal structures of drugs: Advances in determination, prediction and engineering. Nat Rev Drug Discov 3(1):42-57.
11. Brittain HG. 2012. Polymorphism and solvatomorphism 2010. J Pharm Sci 101(2):464-484.
12. Bauer J, Spanton S, Henry R, Quick J, Dziki W, Porter W, Morris J. 2001. Ritonavir: An extraordinary example of conformational polymorphism. Pharm Res 18(6):859-866.
13. Chamarthy S, Pinal R. 2008. The nature of crystal disorder in milled pharmaceutical materials. Colloids Surf A: Physicochem Eng Aspects 331(1-2):68-75.
14. Chattoraj S, Bhugra C, Telang C, Zhong L, Wang Z, Sun CC. 2011. Origin of two modes of non-isothermal crystallization of glasses produced by milling. Pharm Res 29(4):1020-1032.
15. De Gioannis B. 2004. Morphology and growth control of griseofulvin recrystallized by compressed carbon dioxide as antisolvent. J Cryst Growth 262(1-4):519-526.
16. Feng T, Bates S, Carvajal MT. 2009. Toward understanding the evolution of griseofulvin crystal structure to a mesophase after cryogenic milling. Int J Pharm 367(1-2):16-19.
17. Feng T, Pinal R, Carvajal MT. 2008. Process induced disorder in crystalline materials: Differentiating defective crystals from the amorphous form of griseofulvin. J Pharm Sci 97(8):3207-3221.
18. Jarmer DJ, Lengsfeld CS, Anseth KS, Randolph TW. 2005. Supercritical fluid crystallization of griseofulvin: Crystal habit modification with a selective growth inhibitor. J Pharm Sci 94(12):2688-2702.
19. Puttaraja, Nirmala KA, Sakegowda DS, Duax WL. 1982. Crystal structure of griseofulvin. J Crystallogr Spectrosc Res 12(5):415-423.
20. Trasi NS, Boerrigter SXM, Byrn SR. 2010. Investigation of the milling-induced thermal behavior of crystalline and amorphous griseofulvin. Pharm Res 27(7):1377-1389.
21. Willart J-F, Carpentier L, Danède F, Descamps M. 2012. Solid-state vitrification of crystalline griseofulvin by mechanical milling. J Pharm Sci 101(4):1570-1577.
22. Elamin AA, Ahlneck C, Alderborn G, Nyström C. 1994. Increased metastable solubility of milled griseofulvin, depending on the formation of a disordered surface structure. Int J Pharm 111(2):159-170.
23. Tombari E, Presto S, Johari GP, Shanker RM. 2007. Molecular mobility, thermodynamics and stability of griseofulvin's ultraviscous and glassy states from dynamic heat capacity. Pharm Res 25(4):902-912.
24. Burger A, Ramberger R. 1979. On the polymorphism of pharmaceuticals and other molecular crystals. II. Applicability of thermodynamic rules. Mikrochim Acta II(3-4):273-316.
25. Burger A, Ramberger R. 1979. On the polymorphism of pharmaceuticals and other molecular crystals. I. Theory of thermodynamic rules. Mikrochim Acta II(3-4):259-271.
26. Ribeiro MENP, de Moura CL, Vieira MGS, Gramosa NV, Chaibundit C, de Mattos MC, Attwood D, Yeates SG Nixon SK, Ricardo NMPS. 2012. Solubilisation capacity of Brij surfactants. Int J Pharm 436(1-2):631-635.
27. Zhou D, Zhang GGZ, Law D, Grant DJW, Schmitt EA. 2008. Thermodynamics, molecular mobility and crystallization kinetics of amorphous griseofulvin. Mol Pharm 5(6):927-936.
28. Zhu L, Jona J, Nagapudi K, Wu T. 2010. Fast surface crystallization of amorphous griseofulvin below T g. Pharm Res 27(8):1558-1567.